Phase 4CompletedAge-related condition

Behavior and Exercise Versus Drug Treatment in Men With Nocturia (BEDTiMe)

Sponsor
Atlanta VA Medical Center (US federal)
Enrollment
72 enrolled
Conditions
Nocturia
Interventions
Behavioral; tamsulosin (alpha-adrenergic antagonist medication); placebo; placebo
Ages
adults, older adults
Registry
NCT00824200

Full record on ClinicalTrials.gov

From the registry

Nocturia, waking at night from sleep to void, is a prevalent and troublesome symptom. Treatment with an alpha-adrenergic antagonist medication (α-blockers) is a standard therapy for LUTS in men, but α-blockers offer only limited reductions in nocturia. While combinations of multiple drugs could be used, many individuals wish to take fewer medications. Participants in the BEDTiMe Nocturia Study will undergo a series of visits during which they will receive a combination of either standard drug therapy (or placebo) and a behavioral intervention tailored to help with nocturia or problems with nocturia. Participants will be evaluated for outcomes at 12 weeks and followed for six months. This study will yield important information related to alternative treatments of nocturia in men, as well as novel information regarding the clinical importance of these nocturia reductions. This study has the potential to alter standards of care.

Primary outcomes

  • Nocturia episodes (voiding diary)

History

  1. Last registry update

  2. Study completion

  3. Primary completion

  4. Registered

  5. Started

Papers citing this trial